<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382248</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104469</org_study_id>
    <nct_id>NCT04382248</nct_id>
  </id_info>
  <brief_title>The Integration of a Mobile App Platform With Biomarkers in Kidney Transplantation</brief_title>
  <official_title>Next Generation Self Management: The Integration of a Mobile App Platform With Biomarkers in Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CareDx, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the feasibility and acceptability of a mobile app to
      improve self-management skills and medication adherence in kidney transplantation, to assess
      the clinical benefit of mobile app in combination with tailored coaching using text messaging
      to enhance patient activation, self-management and medication adherence and to determine
      whether immunological biomarkers such as cell-free DNA and donor specific antibodies are
      associated with self-management and medication adherence.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in patient activation scores as measured by Patient Activation Measure</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
    <description>0-100 scale that segments patients into one of four activation levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in self-management as measured by Partners In Health survey</measure>
    <time_frame>baseline, 3 months, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication adherence as measured by self-tracking</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication adherence as measured by blood levels</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of cell-free DNA</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of donor-specific antibodies</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allograft function as measured by urine protein/creatinine ratio</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allograft function as measured by serum creatinine</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Medication Compliance</condition>
  <arm_group>
    <arm_group_label>Interventional Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An app for tracking medications, receiving personal coaching and educational material</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An app for tracking medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smartphone App</intervention_name>
    <description>An app for monitoring medications, blood pressure, exercise, healthy eating</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Interventional Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Tailored education</intervention_name>
    <description>in-person coaching</description>
    <arm_group_label>Interventional Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) age 12-40 kidney transplant recipients with stable kidney function at least one
             month from the time of transplantation

          -  2) have and use a smartphone

          -  3) patients without pre-formed antibodies

        Exclusion Criteria:

          -  1) Patients &lt;12 or &gt;40

          -  2) patient with pre-existing antibodies

          -  3) patients with rejection at the time of enrollment

          -  4) patients without a smartphone

          -  5) patients with developmental delay or psychological impairment and unable to use an
             app
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eileen Chambers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynnette Moats, MSN RN</last_name>
    <phone>9196813399</phone>
    <email>lynnette.moats@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lynnette Moats</last_name>
      <phone>919-681-3399</phone>
      <email>lynnette.moats@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>teens</keyword>
  <keyword>mobile app</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

